ArticleApplied health economics and health policy2025
Measures of Performance and Clinical Superiority Thresholds for 'Test-and-treat' Predictive Biomarkers.
Article in Applied health economics and health policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPredictive biomarkers are intended to predict an individual's expected response to specific treatments. These are an important component of precision medicine. We explore measures of biomarker performance that are based on the expected probability of response to individual treatment conditional on biomarker status. We show how these measures can be used to establish thresholds at which testing strategies will be clinically superior.
methodsWe used a decision model to compare expected probabilities of response of treat-all and test-and-treat strategies. Based on this, R-Shiny-based apps were developed which produce plots of the threshold positive and negative predictive values or sensitivities and specificities above which a 'test-and-treat' strategy will outperform a 'treat-all' strategy. We present a case study using data on the use of RAS status to predict response to panitumumab in metastatic colorectal cancer.
resultsWhere a companion diagnostic is predictive of response to one of the treatments being compared, it is possible to estimate threshold sensitivities and specificities above which a testing strategy will outperform a treat-all strategy, based only on the odds ratio of response. Where negative and positive predictive values were used, the threshold depended on the prevalence of the biomarker-positive patients. DISCUSSION: These intuitive performance measures for predictive biomarkers, based on expected response to individual treatments, can be used to identify promising candidate companion diagnostic tests and indicate the potential magnitude of the net benefit of testing.
Indexed as
Identifiers
39222295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.